BioSyent Schedules Q4 and Full Year 2022 Earnings Release for March 21, 2023
09 mars 2023 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 09, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended...
BioSyent annonce le lancement du nouveau FeraMAX(MD) Pd Entretien 45
07 mars 2023 16h01 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, 07 mars 2023 (GLOBE NEWSWIRE) -- À la veille de la Journée internationale des femmes, BioSyent Inc. (« BioSyent », « la Société », « Bourse de croissance TSX » : RX) célèbre le...
BioSyent Announces Launch of New FeraMAX® Pd Maintenance 45
07 mars 2023 16h01 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, March 07, 2023 (GLOBE NEWSWIRE) -- On the eve of International Women’s Day, BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) celebrates the Canadian launch of...
BioSyent Declares First Quarter 2023 Dividend
01 févr. 2023 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
14 déc. 2022 16h50 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an...
BioSyent Announces Renewal of Normal Course Issuer Bid
13 déc. 2022 08h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that the TSX Venture Exchange (“TSX-V”) has accepted the...
BioSyent Releases Q3 and YTD 2022 Financial Results
16 nov. 2022 19h07 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022. Key...
BioSyent Schedules Q3 and YTD 2022 Earnings Release for November 16, 2022
10 nov. 2022 09h00 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and nine months ended...
BioSyent Initiates First Dividend
12 oct. 2022 17h45 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly...
BioSyent to Present at the Virtual MicroCap Leadership Summit
14 sept. 2022 16h30 HE
|
BioSyent Inc.
MISSISSAUGA, Ontario, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been selected to present at the 7th annual...